Mammary Cell News Volume 7.18 | May 14 2015

Paclitaxel Targets FOXM1 to Regulate KIF20A in Mitotic Catastrophe and Breast Cancer Paclitaxel Resistance
Scientists showed that FOXM1 depletion can sensitize breast cancer cells and mouse embryonic fibroblasts into entering paclitaxel-induced senescence, with the loss of clonogenic ability, and the induction of senescence-associated β-galactosidase activity and flat cell morphology. [Oncogene] Full Article

Functional Screening Identifies MCT4 as a Key Regulator of Breast Cancer Cell Metabolism and Survival
Scientists identified selective metabolic dependencies in breast cancer by investigating 17 breast cancer cells lines representative of the genetic diversity of the disease. They demonstrated that the monocarboxylate transporter 4 (MCT4) is an important regulator of breast cancer cell survival. [J Pathol] Abstract

Let-7a Regulates Mammosphere Formation Capacity through Ras/NF-κB and Ras/MAPK/ERK Pathway in Breast Cancer Stem Cells
The authors illustrated that overexpression of let-7a reduced cell proliferation and mammosphere formation ability of breast cancer stem cells in a KRas-dependent manner through different pathways in vitro and in vivo. [Cell Cycle] Abstract

Redox Signaling to Nuclear Regulatory Proteins by Reactive Oxygen Species Contributes to Estrogen-Induced Growth of Breast Cancer Cells
Investigators demonstrated of oxidative modification of phosphatases PTEN and CDC25A by 17β-Estradiol (E2)-generated reactive oxygen species (ROS) along with the subsequent activation of AKT and ERK pathways that culminated in the activation of nuclear respiratory factor-1 leading to the upregulation of cell cycle genes. E2-induced ROS by influencing nuclear proteins p27 and Jab1 also contributed to the growth of MCF-7 cells. [Br J Cancer] Abstract

CD44 Expression Contributes to Trastuzumab Resistance in HER2-Positive Breast Cancer Cells
Researchers hypothesized that CD44 contributes to trastuzumab resistance independently of its role as a cancer stem cell marker. They used trastuzumab-sensitive breast cancer cell lines and their trastuzumab-resistant isogenic counterparts to evaluate the role of CD44 in response to trastuzumab. [Breast Cancer Res Treat] Abstract

Targeting of miR9-NOTCH1 Interaction Reduces Metastatic Behavior in Triple Negative Breast Cancer
Scientists appraised microRNA-9 (miR-9) correlation with NOTCH1 involved in Notch signaling in metastatic breast cancer. They found that miR-9 expression was decreased in MDA-MB-231 breast cancer cells compared with MCF-10A normal breast cell line. [Chem Biol Drug Des] Abstract

CLINICAL RESEARCH

UNICANCER-PEGASE 07 Study: A Randomized Phase III Trial Evaluating Post-Operative Docetaxel-5FU Regimen after Neo-Adjuvant Dose-Intense Chemotherapy for Treatment of Inflammatory Breast Cancer
Researchers evaluated the benefit of adding docetaxel-5 fluorouracil (5FU) regimen after pre-operative dose-intense epirubicin-cyclophosphamide and loco-regional treatment in inflammatory breast cancer patients. [Ann Oncol] Abstract

A Phase I Study with Dose Expansion of the CDK Inhibitor Dinaciclib (SCH 727965) in Combination with Epirubicin in Patients with Metastatic Triple Negative Breast Cancer
A Phase I study was conducted to determine the maximum tolerated dose of dinaciclib in combination with epirubicin in patients with metastatic triple negative breast cancer. [Invest New Drugs] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Corcept Therapeutics’ Mifepristone Combined with Eribulin to Improve Antitumor Activity in Patients with Triple-Negative Breast Cancer
Corcept Therapeutics Incorporated announced results of a multi-center Phase I/II dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven^®) that show it is well tolerated and clinically active in patients with triple-negative breast cancer. [Press release from Corcept Therapeutics Incorporated discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | Abstract

Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Puma Biotechnology, Inc. announced the release of abstracts on its drug candidate PB272 (neratinib) [Press release from Puma Biotechnology, Inc. discussing research to be presented at the 2015 ASCO Annual Meeting, Chicago] Press Release | Abstract 1 | Abstract 2

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

Redx Reaches Pre-Clinical Proof of Concept with Oncology Lead
Redx Pharma has reached pre-clinical proof of concept stage with an advanced lead which has the potential to tackle some of the most hard-to-treat cancers. The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signaling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. [Redx Pharma Plc] Press Release

Yang Receives AACR Career Development Award
Shih-Hsin Yang, M.D., Ph.D., associate professor at the University of Alabama at Birmingham, has been awarded the 2015 American Association for Cancer Research (AACR)-Triple Negative Breast Cancer Foundation Career Development Award for clinical/translational research. [University of Alabama at Birmingham] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

NEW Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

PhD Student – Epigenetic Editing to Mimic and Reverse Breast Cancer Resistance (University Medical Center Groningen)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Postdoctoral Position – ER Stress and Cancer Biology (Baylor College of Medicine)

Postdoctoral Research Fellow – Prostate Cancer and Breast Cancer (Baylor College of Medicine)

Postdoctoral Fellow – Breast Cancer & Stem Cell Biology (University of Cincinnati)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.